Skip to main content

Table 1 Clinical characteristics of 67 children with nosocomial K. pneumoniae bloodstream infection

From: Time to appropriate antimicrobial therapy serves an independent prognostic indicator in children with nosocomial Klebsiella pneumoniae bloodstream infection

Characteristics

Number/median

Percent/IQR

Demographic characteristics

 Male (n, %)

42

61.69

 Age (years) (median, IQR)

4.33

0.76–10.67

Underlying conditions

 Hematologic malignancy (n, %)

44

65.67

 Immunosuppression (n, %)

41

61.19

 Congenital heart disease (n, %)

14

20.90

Sources of infection

 Respiratory tract (n, %)

37

55.22

 Gastrointestinal tract (n, %)

14

20.90

Unknown source (n, %)

10

14.93

 Invasive operation (n, %)

5

7.46

 Urinary tract (n, %)

1

1.49

Drug resistant bacteria phenotypes

 Sulbactam resistant (n, %)

40

59.70

 Extended spectrum beta-lactamase (n, %)

32

47.76

 Cephalosporin resistant (n, %)

15

22.39

 Tazobactam resistant (n, %)

14

20.90

 Carbapenem resistant (n, %)

7

10.45

 Multidrug resistant (n, %)

6

8.96

 Aminoglycoside resistant (n, %)

4

5.97

Empiric antimicrobial treatment

 Carbapenem (n, %)

38

56.72

 Fourth-generation cephalosporin (n, %)

9

13.43

 Third-generation cephalosporin (n, %)

8

11.94

 Tazobactam (n, %)

7

10.45

 Second-generation cephalosporin (n, %)

3

4.48

 Sulbactam (n, %)

2

2.99

Length of stay before the onset of bloodstream infection (days) (median, IQR)

13.68

6.59–17.53

Length of hospitalization stay (days) (median, IQR)

28.96

20.04–42.75

The peak of temperature (centigrade) (median, IQR)

39.8

39.3–40.1

Antimicrobials administrated prior to blood culture (n, %)

28

41.79

With secondary hypoalbuminemia during hospitalization (n, %)

22

32.84

PRISM III score (median, IQR)

8

3–9

TTP (h) (median, IQR)

14.12

12.72–16.22

TTAT (h) (median, IQR)

4.52

0.97–14.18

Need for invasive mechanical ventilation (n, %)

11

16.42

Septic shock (n, %)

12

17.91

In-hospital mortality (n, %)

9

13.43

  1. Abbreviations: IQR inter-quartile range, PRISM pediatric risk of mortality, TTAT time to appropriate therapy, TTP time to positivity